Hansa Medical AB (STO:HMED), a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases, reported on Thursday a net loss of SEK58,796,000, or SEK1.55 per share, for the second quarter of 2018, from April 2018 to June 2018.

This was a decline over a net loss of SEK45,151,000, or SEK1.28 per share, in Q2 2017.

Net revenues for the quarter were SEK900,000, as compared with SEK693,000 in Q2 2017.

Hansa Medical's lead product, imlifidase (IdeS), is a proprietary antibody-degrading enzyme currently in late -stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications.

(EUR1.00=SEK10.38)